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Abstract
Background: Aberrant methylation of promoter DNA and transcriptional repression of specific tumor suppressor genes play
an important role in carcinogenesis. Recently, many studies have investigated the association between cigarette smoking
and p16
INK4a gene hypermethylation in lung cancer, but could not reach a unanimous conclusion.
Methods and Findings: Nineteen cross-sectional studies on the association between cigarette smoking and p16
INK4a
methylation in surgically resected tumor tissues from non-small cell lung carcinoma (NSCLC) patients were identified in
PubMed database until June 2011. For each study, a 262 cross-table was extracted. In total, 2,037 smoker and 765
nonsmoker patients were pooled with a fixed-effects model weighting for the inverse of the variance. Overall, the frequency
of p16
INK4a hypermethylation was higher in NSCLC patients with smoking habits than that in non-smoking patients
(OR=2.25, 95% CI=1.81–2.80). The positive association between cigarette smoking and p16
INK4a hypermethylation was
similar in adenocarcinoma and squamous-cell carcinoma. In the stratified analyses, the association was stronger in Asian
patients and in the studies with larger sample sizes.
Conclusion: Cigarette smoking is positively correlated to p16
INK4a gene hypermethylation in NSCLC patients.
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Introduction
The incidence of lung cancer is increasing worldwide,
particularly in developing countries. In China the death rate of
lung cancer has been increasing from 7.1 to 30.8 per 100,000
during 1975–2005. People dying due to lung cancer accounted for
23% of total amount of cancer death in 2005 [1]. 80% of primary
lung cancers are non-small cell lung carcinoma (NSCLC) which is
characterized by a long asymptomatic latency and poor prognosis.
Without an early diagnostic approach, over 40% of lung cancer
patients develop metastasis at the time of diagnosis and survive for
a short time period under a conventional chemotherapy [2]. Only
15% of NSCLC patients can survive over 5 years [3]. Thus, it is
essential to identify biomarkers for early prediction of lung cancer.
Cigarette smoking is a well known driving force for lung cancer
development. The lifetime risk of developing lung cancer is 17.2%
in male smokers and 11.6% in female smokers, which is much
higher than that in nonsmokers with 1.3% in male and 1.4% in
female [4]. Although most lung cancers are associated with
cigarette smoking, it is statistically estimated that 15% of them in
males and 53% in females, accounting for about 25% of all lung
cancers, are not attributable to cigarette smoking [3]. Lung
cancers arising in nonsmokers are more frequently adenocarcino-
mas, affect females disproportionately more than males, and have
regional differences ranging from 10–15% in Europe and North
America to 30–40% in Asian countries [5–7]. Moreover,
nonsmoker lung cancers have improved survival and are more
sensitive to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor therapy. It might be due to that the activation of
EGFR by gene mutations appears more often in nonsmoker lung
cancers [5,6]. Taken together, lung cancer in nonsmokers would
probably be considered a separate cancer category. If so, it would
rank as the seventh most common cause of cancer death
worldwide [3]. However, whether these clinical-pathological and
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smokers are related to cigarette smoking is still unknown.
The interest in cancer-associated changes in gene methylation
has grown enormously in recent years with the speculation that the
promoter methylation status may provide an early biomarker for
tumorigenesis [8]. Silencing of genes by aberrant promoter
hypermethylation has been recognized as a key event in cancer
initiation and progression [9,10]. Highly sensitive assays such as
methylation-specific PCR (MSP), which could detect one meth-
ylated allele in the presence of 10
3–10
4 unmethylated alleles
[11,12], have been used to assess gene-promoter methylation in
primary tumors, serum, plasma, sputum or specimens from the
aerodigestive tract epithelium [13]. Numerous studies have
investigated the methylation statuses of specific genes in body
fluids and tumor tissues of lung cancer patients, and identified
more than 60 genes as being epigenetically silenced in lung tumors
[8]. The proof-of-concept studies suggested that gene-specific
promoter methylation occurs as an early event in lung cancer. For
example, hypermethylation of p16
INK4a (also known as cyclin-
dependent kinase inhibitor 2A, CDKN2A)o rO
6-methylguanine-
DNA methyltransferase (MGMT) was found in sputum samples 5
to 36 months prior to clinical diagnosis [14]. Moreover, the
frequency of p16
INK4a hypermethylation increased progressively
from 17% in basal-cell hyperplasia to 24% in squamous
metaplasia, and to 60% in squamous cell carcinomas [15]. The
correlation between gene methylation and recurrence of lung
cancer has also been reported [16,17]. The promoter hyper-
methylation of several genes including p16
INK4a, cadherin 13
(CDH13), Ras association (RalGDS/AF-6) domain family member
1( RASSF1A) and adenomatous polyposis coli (APC) in NSCLC
specimens is associated with early recurrence after surgery [17].
Moreover, the reversibility of DNA methylation modification
makes it possible that the expression of genes that have undergone
epigenetic silencing becomes reactivated by the inhibitors of DNA
methylation. Many agents such as 5-azacytidine and zebularine
are currently being tested in clinical trials [18]. Despite the
significance of gene promoter methylation in predicting incidence
or prognosis and in epigenetic therapy of lung cancer, the manner
in which these epigenetic lesions accumulate during carcinogenesis
is not completely understood. The missing links among environ-
mental factors, DNA methylation changes, and lung cancer limit
the applications of methylated genes as a biomarker for early
detection of lung cancers.
The correlation between cigarette smoking and aberrant gene
methylation has been extensively studied, but the results are
inconsistent and inconclusive. The present study mainly focused
on p16
INK4a gene as it is the first gene identified in lung cancer, and
is transcriptionally silenced predominantly through aberrant
promoter hypermethylation [19]. Here, we performed a litera-
ture-based systematic review and meta-analysis to quantitatively
analyze the correlation between cigarette smoking and p16
INK4a
gene methylation in NSCLC patients.
Methods
Ethics Statement
An ethics statement was not required in this study.
Literature search
We systematically searched for all published articles indexed in
PubMed database from 1966 to June 18, 2011 with the Medical
Subject Headings (MeSH) and corresponding free text: ‘‘smok*
AND (p16* OR CDKN2A OR INK4A) AND (methylation OR
epigene*)’’. We also manually searched the references of these
publications in order to retrieve additional studies. Only those
published as full-text articles and in English or in Chinese were
included as candidates.
Inclusion and exclusion criteria
Studies were selected for analysis if they met the following
criteria: 1) they were original epidemiological studies on the
correlation between cigarette smoking and p16
INK4a methylation;
2) they were conducted in lung cancer patients; 3) the specimens
used for methylation analysis must include surgically resected
primary tumor samples, while other specimens such as sputum,
serum, bronchial lavage samples and normal or non-malignant
lung tissue may be used, but not essential; 4) p16
INK4a methylation
status was examined using methylation-specific PCR (MSP) or
quantitative MSP (QMSP); 5) the subjects in every study
comprised nonsmokers and smokers (former smokers and/or
current smokers), irrespective of minor discrepancies of the
definition of nonsmokers over all studies. To avoid duplication
of data, we carefully checked the author names, research
institutions and procedures for enrolling participants. Where
several publications reported from the same population data, only
the most rounded study with more information was included.
Data collection
For each eligible study, we collected information regarding
authors, year and source of publication, country of origin,
inclusion criteria, exclusion criteria, histology of lung cancer,
types of biological specimen, number of participants, participants’
age and gender, smoking behaviour, p16
INK4a methylation
frequencies in nonsmokers and smokers and the method for
methylation detection. All included studies used nonsmokers as a
control group, though some of them did not provide the definition
of nonsmoker. In studies defining nonsmoker, there were three
different definitions of nonsmoker: (1) daily cigarette consump-
tion6years of smoking=0; (2) less than 100 cigarettes in entire
lifetime; (3) less than 20 pack-years. Since it is impossible to
redefine nonsmoker based on a unified standard, we combined
nonsmokers in our meta-analysis according to their original group
in each individual study. Correspondingly, subjects except
nonsmokers were smokers comprising former smokers and current
smokers, and light, moderate or heavy smokers. Then data was
integrated in 262 tables demonstrating the methylation/unmethy-
lation of p16
INK4a gene according to the cigarette smoking status
(smoker/nonsmoker). All data were extracted independently by
two reviewers using a standard form. Minor discrepancies were
resolved by the authors’ discussion.
Meta-analysis and statistical analysis
The foremost analysis examined the differences in the frequency
of p16
INK4a methylation in lung cancer tissues between smoker and
nonsmoker patients. Summary OR was obtained across all studies.
Heterogeneity was examined using the I
2 statistic, which
represents the proportion of variation in the effect sizes that is
attributable to true differences across studies rather than to a
random error. Results without heterogeneity were pooled using
the fixed-effect model, following the Mantel-Haenszel method.
Otherwise, the random effect analysis with the method of
DerSimonian and Larid was used.
The meta-analyses were performed using Stata statistical
software (version 10.0, Stata Corporation, College Station, Texas,
USA). Results were shown in forest plots, where the sizes of the
boxes for individual studies were inversely proportional to the
variances of the log relative risks, and the horizontal lines represent
95% confidence interval (CI).
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INK4a methylation in smokers and
nonsmokers were compared by Wilcoxon signed rank test. The
coefficients of Spearman’s rank correlation were calculated
between frequency of p16
INK4a methylation and sample size.
These analyses were performed using SPSS for Windows (version
11.5, SPSS Inc., Chicago, IL, USA).
Results
Study characteristics
Following the inclusion and exclusion criteria described above,
19 studies [12,20–37] were included in the analysis (Figure 1). The
characteristics of these studies are summarized in Table 1. Of
these 19 studies, eight defined the subtypes (adenocarcinoma or
squamous cell carcinoma) of NSCLCs. Ten studies were
conducted in Asia (2 in China, 6 in Japan and 2 in Korea), five
were in USA, and the remaining four were in Australia, Greece,
Chile, and multi-areas in Asia-Pacific regions (USA, Australia,
Japan and Taiwan) respectively (Table 1). In two studies [12,25],
lung adenocarcinoma (AC) patients and squamous cell carcinoma
(SCC) patients were analyzed separately, therefore they were
treated as separate items in the meta-analysis. As for the primer
sequences of MSP, 15 studies used the same primers designed by
Herman et al. in 1996 [11]. The primer sequences for detecting
methylated p16
INK4a gene were 59-TTA TTA GAG GGT GGG
GCG GAT CGC-39 (sense) and 59-GAC CCC GAA CCG CGA
CCG TAA-39 (antisense). The size of the PCR product for the
methylated reaction was 150 bp. The primer sequences used for
the unmethylated promoter were 59-TTA TTA GAG GGT GGG
GTG GAT TGT-39 (sense) and 59-CAA CCC CAA ACC ACA
ACC ATA A-39 (antisense). The size of the PCR product for the
unmethylated reaction was 151 bp.
Combined results and subgroup analyses
In general, the frequencies of p16
INK4a methylation ranged from
19 to 83% (median 34%) in smoker patients, which were much
higher than those in nonsmoker patients with range from 0 to 91%
(median 20%). In the meta-analysis, 2802 NSCLC patients
including 2037 smokers and 765 nonsmokers were included in
pooling the overall correlation estimation. Under the fixed-effects
model, the pooled odds ratio (OR) of p16
INK4a methylation in
smoker patients, compared to nonsmoker patients, was 2.25 with
95% CI=1.81–2.80 (Figure 2). Of six studies only including AC
patients, the subgroup analysis showed no significant difference in
Figure 1. Flow diagram of the stepwise selection from associated studies.
doi:10.1371/journal.pone.0028882.g001
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INK4a methyl-
ation when comparing AC patients (OR=2.38, 95%CI=1.75–
3.23) (Figure 3) and all NSCLC patients (OR=2.25, 95%
CI=1.81–2.80).
Because there was a borderline significant but moderate degree
of heterogeneity among the 19 studies (I
2=33.1%, P=0.072), we
performed sensitivity analyses to identify potential sources of
heterogeneity. Stratification by sample size showed a stronger
association in larger-size (.100 patients per study) studies
(OR=2.39, 95% CI=1.88–3.05, Figure 4A) than that in
smaller-size studies (OR=1.72, 95% CI=1.04–2.84, Figure 4B).
Stratified analysis also revealed that the associations varied among
the subjects from different regions. The association between
cigarette smoking and p16
INK4a methylation tended to be stronger
in 9 Asian studies (OR=2.63, 95%CI=1.92–3.61) (Figure 5A)
compared to the 5 North American studies (OR=1.62,
95%CI=1.13–2.34) (Figure 5B). In addition, there was no inter-
study heterogeneity in Asian studies (I
2=0,P=0.709).
Four of the 19 included studies [12,21,23,31] and another two
excluded studies [38,39] had compared the frequencies of p16
INK4a
methylation in adjacent noncancerous tissues or sputum specimens
from NSCLC patients with or without smoking habits and no
significant differences were found (Table S1). In another 7
excluded studies [40–46], p16
INK4a methylation was examined in
sputum, bronchial lavage samples or blood specimens from
cancer-free subjects. We failed to find a link between cigarette
smoking and the frequency of p16
INK4a methylation (Table S2,
Figure S1). These results suggested that cigarette smoking had no
impact on p16
INK4a hypermethylation in the surrogate samples
from NSCLC patients, and that the positive association between
cigarette smoking and p16
INK4a hypermethylation was not present
in health conditions.
Publication bias
To ensure the quality of this study, we performed a Begger’s
funnel plot and Egger’s tests to eliminate the publication bias of
included studies. As shown in Figure 6, the shapes of the funnel
plots showed a little asymmetry at the bottom. However, Egger’s
test, which provided statistical data of funnel plot symmetry, did
not show any evidence of publication bias (t=0, P=0.998).
Discussion
The present study, based on the accumulated evidences from 19
cross-sectional studies, indicates that cigarette smoking is positively
related to p16
INK4a hypermethylation in tumor tissues from
NSCLC patients. The frequency of p16
INK4a methylation in
smoker lung cancer patients was 2.25 times higher than that in
nonsmoker patients. The association appeared to be stronger in
Asian patients and in studies with a larger number of subjects, but
without a histology (AC or SCC) specificity. However, this positive
correlation did not exist in adjacent noncancerous tissues from
NSCLC patients and in biological specimens of ‘healthy’ subjects
without cancer. Given the results that cigarette smoking leading to
p16
INK4a hypermethylation was related to the stage progression of
tumorigenesis, we speculated that p16
INK4a hypermethylation
might be an early marker for cancer diagnosis, particularly in
cigarette smoking patients.
Recent epidemiological studies have revealed that molecular
mechanisms underlying the development of lung cancers differed
Table 1. Characteristics of studies on the overall relationship between cigarette smoking and p16 methylation in lung cancer
patients.









Sanchez-Cespedes [19] 2001 USA NSCLC 6663 47 7/33 5/14
Zochbauer-Muller [20] 2001 Australia NSCLC 28–81 107 27/98 0/9
Kim [21] 2001 USA NSCLC 67611 185 49/172 2/13
Yanagawa [22] 2002 Japan NSCLC 6762 51 13/37 1/14
Toyooka [12] 2003 Asia-Pacific AC 26–87 295 47/183 6/112
Toyooka [12] 2003 Asia-Pacific SCC 26–87 189 58/172 5/17
Yanagawa [23] 2003 Japan NSCLC 39–86 75 21/55 2/20
Toyooka [24] 2004 Japan AC No data 217 29/120 10/97
Toyooka [24] 2004 Japan SCC No data 138 46/130 1/8
Kim [25] 2004 Korea SCC No data 125 37/117 3/8
Divine [26] 2005 USA AC 33–86 203 81/157 18/46
Liu [27] 2006 USA NSCLC 65610 122 51/81 13/41
Nakata [28] 2006 Japan NSCLC 40–85 202 38/139 9/63
Toyooka [29] 2006 Japan AC No data 164 24/86 7/78
Georgiou [30] 2007 Greece NSCLC 45–75 27 20/24 2/3
Guzman [31] 2007 Chile NSCLC 6669 65 39/54 10/11
Kim [32] 2007 Korea NSCLC 41–82 99 18/79 4/20
Tessema [33] 2009 USA AC 66 175 67/100 48/75
Wang [34] 2010 China AC 46–84 56 9/20 10/36
Yanagawa [35] 2011 Japan AC 39–86 62 7/36 2/26
Zhang [36] 2011 China NSCLC 32–79 198 82/144 18/54
doi:10.1371/journal.pone.0028882.t001
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frequently activated by gene mutations in nonsmoker lung cancers,
while mutations of KRAS often occur in smoker lung cancer.
However, the mutations in either gene in lung adenocarcinomas
are rarely seen although the biological consequences of KRAS and
EGFR mutations share similarities in regulation of cell prolifer-
ation, survival and apoptosis [47,48]. In the present study, we
demonstrate that the frequency of p16
INK4a hypermethylation is
slightly but significantly higher in smoker patients than that in
nonsmoker patients. It is well known that p16
INK4a plays an
essential role in the development of most human cancers for the
reason that the p16/cyclinD1/CDK4/RB signaling pathway
controls the cell cycle at the G1/S transition [49]. Hypopho-
sphorylated RB inhibits G1/S transition by binding to E2F1
transcription factor and exerts its tumor-suppressor function. Once
hyperphosphorylated by the cyclinD1/CDK4 complex, RB
releases E2F1, which results in transition from G1 to S phase.
p16 prevents RB from phosphorylation by inhibition of CDK4,
leading to a cell cycle arrest. Suppression of p16 expression allows
unregulated phosphorylation of the RB protein and leads to
uncontrolled cell cycle progression and cell division [50]. p16
INK4a
has a low frequency of mutations in lung cancer [51]. Its
inactivation is mainly through gene promoter hypermethylation
[19]. For example, Nakata et al. found that in tumors with
p16
INK4a hypermethylation, 63.3% showed reduced expression;
whereas, in tumors without p16
INK4a hypermethylation, only
33.7% showed reduced expression (P=0.0002) [29]. The positive
correlation between cigarette smoking and p16
INK4a hypermethy-
lation demonstrates that cigarette smoking plays an important role
in determining the molecular signatures involved in lung cancer
development.
The mechanism for cigarette smoking inducing gene-specific
hypermethylation, e.g. p16
INK4a, remains unclear. De novo meth-
ylation uses S-adenosyl-methionine as a methyl donor and adds a
methyl group to the cytosine ring to form methyl cytosine, which is
catalyzed by DNA methyltransferases (DNMT) 1, 3a, or 3b [52].
It is estimated that DNMT1 is responsible for about 90% of
methyltransferase activity in mammalian cells [53]. DNMT1
overexpression was found in many types of cancers including lung
cancers, particularly in patients who were smokers [54–56]. A
recent study found that DNMT1 was highly expressed in tumor
tissues in a dose response manner compared with the non
neoplastic stroma tissues, not only in tobacco-specific carcinogen
nicotine-derived nitrosamine ketone (NNK)-induced mouse lung
cancer but also in human lung cancer associated with cigarette
smoking [57]. Moreover, it was demonstrated that NNK increased
DNMT1 expression and activity by blocking its degradation
related to ubiquitin-proteasome [57]. AKT/GSK3b/bTrCP
Figure 2. Meta-analysis of cigarette smoking and p16
INK4a methylation in all NSCLC patients.
doi:10.1371/journal.pone.0028882.g002
Cigarette Smoking and p16
INK4a Hypermethylation
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28882signaling is implicated in the accumulation of nuclear DNMT1,
which leads to hypermethylation of p16
INK4a, fragile histidine triad
gene (FHIT) and retinoic acid receptor b (RARB), and ultimately
leads to tumorigenesis and poor prognosis [57]. Although the
direct interaction of DNMT1 to the p16
INK4a gene promoter is not
yet characterized [58], these findings indicated that tobacco-
induced DNMT1 overexpression might be responsible for
maintaining the hypermethylation status of p16
INK4a gene.
Lung cancer in nonsmokers is now a prominent public health
concern. However, the major causes of them have yet not been
identified. Environmental tobacco smoke (ETS), for example,
second-hand smoke, has been recognized as a high risk factor [59–
62]. According to the report from International Agency for
Research on Cancer (IARC), the risk for developing lung cancer
from ETS exposure might reach 35% in men and 25% in women
[63]. Given that cigarette smoking has a cause-effect on p16
INK4a
hypermethylation, ETS exposure may explain, at least partly, the
variable percentage of p16
INK4a hypermethylation in nonsmoker
patients. Other factors such as exposed to asbestos, chromium,
arsenic, cadmium, silica, or nickel, or outdoor air pollutants,
previous lung disease, and dietary factors have also been
implicated in non smoking-related risk [5,6]. But so far there is
still a missing link between environmental factors, p16
INK4a
hypermethylation, and lung cancer, which limits the use of gene-
Figure 3. Meta-analysis of cigarette smoking and p16
INK4a methylation in lung adenocarcinoma patients.
doi:10.1371/journal.pone.0028882.g003
Figure 4. Meta-analysis of cigarette smoking and p16
INK4a methylation in NSCLC patients stratified by sample size. A: sample size
.100. B: sample size ,100. Stratification by sample size showed a stronger association in studies with a relatively larger sample size.
doi:10.1371/journal.pone.0028882.g004
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early stage. Thus, the molecular mechanism underlying lung
cancer, irrespective of tobacco-association, should be further
elucidated.
In this study, we observed that the frequency of p16
INK4a
hypermethylation in NSCLC patients varied among different
studies. The combined frequency in the present meta-analysis
w a sl e s st h a n3 5 % .T h ed i s c r e p a n c ya n dt h er e l a t i v el o w
frequency might be due to the method used for detection of
methylation, the variation in defining cigarette smokers, and
insufficient information of clinical outcome. Although MSP is
sufficiently sensitive, the conditions of PCR may affect the
results to a large extent. The results seemed to be a little
artificial particularly when PCR reaction was performed using
both methylated and unmethylated primers. As for definition of
cigarette smoker or nonsmoker, it lacked a consistent criterion
followed by each investigation. In addition, current smokers and
former smokers were not clearly distinguished, and the quantity
of smoking was not calculated in the meta-analysis due to
limited data. Moreover, insufficient clinical information such as
the stage of NSCLC made it difficult to predict the prognosis
based on the results provided.
In conclusion, cigarette smoking is suggested to be positively
related to p16
INK4a methylation in human NSCLC, highlighting
the potential importance of p16
INK4a promoter methylation in
early cancer diagnosis. Furthermore, it is well known that the risk
for developing lung cancer in smokers is 8 to 13 times higher than
that in nonsmokers, while the risk of p16
INK4a hypermethylation in
lung cancer patients with smoking habits was only 2.2 times
increased than that in nonsmoker patients, we speculate that many
other aberrant epigenetic modifications, together with the genetic
damage are involved in lung cancer development, which needs to
be addressed in further investigation.
Supporting Information
Figure S1 Meta-analysis of cigarette smoking and p16
INK4a
methylation in noncancerous patients.
(TIF)
Table S1 Characteristics of studies on the correlations between
cigarette smoking and p16
INK4a methylation in noncancerous tissue
from cancer patients.
(DOC)
Table S2 Characteristics of studies on the correlation between
cigarette smoking and p16
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Figure 5. Meta-analysis of cigarette smoking and p16
INK4a methylation in NSCLC patient stratified by study region. A: Asian studies. B:
North American studies. The association between cigarette smoking and p16
INK4a methylation tended to be stronger in Asian studies compared to
the North American studies.
doi:10.1371/journal.pone.0028882.g005
Figure 6. Begg’s funnel plot for visual assessment of the
presence of publication bias for all studies included in the
meta-analysis (each study is represented by an open circle).
doi:10.1371/journal.pone.0028882.g006
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